Astec LifeSciences Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Astec LifeSciences Limited's yearly results (2023–2026), compared with Basic Materials companies in India. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: For every ₹100 of sales, ₹65 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹41 tied up three years earlier. More money tied up than 95% of Basic Materials companies in India.
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 91% of Basic Materials companies in India.
- Shareholder Slice Ratio: Share count rose 13% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 89% of Basic Materials companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-0.5×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 91% of Basic Materials companies in India.
Cash Locked Ratio
₹65For every ₹100 of sales, ₹65 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹41 tied up three years earlier.
More money tied up than 95% of Basic Materials companies in India.
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Basic Materials companies in India.
Growth Efficiency Ratio
—Sales fell 29%
Sales fell 29% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-29% / -4%In 3 years sales changed by -29% while total assets changed by -4%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-0.2×Operating cash was negative last year, while some debt falls due within a year.
Lower than 87% of Basic Materials companies in India.
Cash Cushion Ratio
−29%Debt, after subtracting cash, equals 29% of its market value (net debt).
Lower than 74% of Basic Materials companies in India.
Tangible Assets Ratio
97%Of every ₹100 the company owns, ₹97 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 80% of Basic Materials companies in India.
Tangible Net Worth Ratio
94%Of every ₹100 of net worth, ₹94 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 83% of Basic Materials companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Astec LifeSciences Limited made a loss over the last year. Astec LifeSciences Limited owes ₹0.58 for every ₹1 it owns. Astec LifeSciences Limited made a loss in each of the last two years.
Compared with Basic Materials companies in India · latest annual results Mar 2026.
P/E ratio
LossAstec LifeSciences Limited made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
3.82The share price is 3.82 times Astec LifeSciences Limited's book value per share, higher than 78% of Basic Materials companies in India.
Market cap
₹1,491 CrThe total market value of all of Astec LifeSciences Limited's shares at today's price (share price × number of shares), smaller than 53% of Basic Materials companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹391 CrWhat Astec LifeSciences Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹175.30Net worth divided by the number of shares. The share price of ₹669.20 is 3.8 times this, which is the P/B above.
Return on equity (ROE)
-17.3%Astec LifeSciences Limited lost 17.3% of its shareholders' money over the last year, lower than almost all Basic Materials companies in India.
Owes vs Owns
0.58×Astec LifeSciences Limited owes ₹0.58 for every ₹1 it owns (moderate), higher than 85% of Basic Materials companies in India.
Dividend yield
NoneAstec LifeSciences Limited does not currently pay a dividend.
Revenue growth
+18%Revenue rose 18% in the year to Mar 2026, and shrank 11% a year on average over 3 years.
Profit growth
LossAstec LifeSciences Limited made a loss in each of the last two years.
Profit margin
-18.2%Astec LifeSciences Limited lost ₹18 for every ₹100 of revenue.
Interest cover
Not coveredAstec LifeSciences Limited's operating profit did not cover its interest costs in the year to Mar 2026.
Cash vs debt
Net debtAstec LifeSciences Limited had ₹438 Cr more debt than cash (net debt) at Mar 2026.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Astec LifeSciences Limited: ₹1,491 Cr ÷ ₹391 Cr (31 Mar 2026) = 3.8.
What is Astec LifeSciences Limited's return on equity?
Astec LifeSciences Limited lost 17.3% of its shareholders' money over the last year, lower than almost all Basic Materials companies in India.
How much does Astec LifeSciences Limited owe compared with what it owns?
Astec LifeSciences Limited owes ₹0.58 for every ₹1 it owns (moderate), higher than 85% of Basic Materials companies in India.
Does Astec LifeSciences Limited pay a dividend?
No. Astec LifeSciences Limited does not currently pay a dividend.
Is Astec LifeSciences Limited's revenue growing?
Revenue rose 18% in the year to Mar 2026, and shrank 11% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.